Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Grade I acute graft-vs-host disease: Treat or not?

View Full Paper
Ask AI
Bookmark
Share

Authors

NKNikolaos KatsivelosFAFrancis AyukWHWilliam J. Hogan

Discussion

Loading...

Member takes

Overview

Observational analysis shows systemic steroid treatment increases non-relapse mortality in grade I acute graft-versus-host disease, indicating a watch-and-wait strategy is preferable.

Key Points

  • Systemic steroids in grade I acute graft-versus-host disease increased non-relapse mortality from infections.
  • Treatment showed that two-thirds of patients required no systemic treatment, aligning with earlier findings.
  • Analysis using a frailty proportional hazards model demonstrated predicted risk factors for patients receiving steroids.
  • Findings suggest a need for alternative treatments for patients with higher risk factors like minimal residual disease.

Cite This Study

Katsivelos et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e19ehttps://doi.org/10.1182/blood-2025-2461
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effect of GVHD prophylaxis on renal function and survival outcomes in allogeneic hematopoietic cell transplant patients with pre-existing renal impairment2025
  2. 2Stage 0+ lower gastrointestinal (LGI) acute graft-versus-host disease (aGVHD) is associated with high response to non-systemic treatment, low incidence of moderate to severe chronic graft-versus-host disease (cGVHD) and low non-relapse mortality (NRM)2025
  3. 3Longitudinal multiproteomic analysis reveals persistent underlying inflammation in acute graft-versus-host disease patients responding to corticosteroid treatment2025
  4. 4Low incidence of agvhd with ptcy, tacrolimus and post-engraftment low dose ATG-based GvHD prophylaxis in haplo-identical donor transplantation and establish of new predict score for grade II-iv agvhd2025
  5. 5Factors associated with acute and chronic graft-versus-host disease after unrelated donor hematopoietic cell transplantation using posttransplant cyclophosphamide-based GVHD prophylaxis2025